Market Cap (In EUR)
16.08 Million
Revenue (In EUR)
4.73 Million
Net Income (In EUR)
-7.36 Million
Avg. Volume
75.55 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.07-5.3
- PE
- -1.62
- EPS
- -0.63
- Beta Value
- -0.157
- ISIN
- FR0013254851
- CUSIP
- F966A0104
- CIK
- -
- Shares
- 15767168.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Sebastien Peltier HDR, Ph.D.
- Employee Count
- -
- Website
- https://www.valbiotis.com
- Ipo Date
- 2017-06-07
- Details
- Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
More Stocks
-
CENTRUMCentrum Capital Limited
CENTRUM
-
UNI
-
FNFI
-
301015Qingdao Baheal Medical INC.
301015
-
MPO
-
SONESonetel AB (publ)
SONE
-
3409
-
ALL-PBThe Allstate Corporation
ALL-PB